Potential limitations associated with this approach, are the recurrent injection of ASO in the organism, the ability to deliver ASO to the Schwann cells, and the level of silencing PMP22 mRNA; indeed, it is critical to reach the right PMP22 mRNA level in Schwann cells because PMP22 haploinsufficiency results in Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) and PMP22 duplication leads to CMT1A. The gene discussed is PMP22; the disease is hereditary neuropathy with liability to pressure palsies.